28.09.19: Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib's activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years(1) / Largest dataset with longest follow-up of any TRK inhibitor illustrates favorable safety profile across ages and tumor types(1)mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news